In fact, E2 signaling pathways have historically been underutilized to treat metabolic diseases due to the feminizing and cancer promoting effects of E2, but these effects are now known to be attributed to ERα (Clusan et al., 2021; Uenoyama et al., 2021). The gene discussed is ESR1; the disease is cancer.